Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Summary

The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.

Timeline

Start

2016-10-31

Primary completion

2027-12-31

Completion

2029-12-31

Drugs

Indications